Dr Reddy's delays semaglutide supplies due to API issue
The story in brief
Dr Reddy's identified an issue with certain batches of semaglutide tablets under the brand name Obeda, affecting their specification due to an active pharmaceutical ingredient problem. The company is investigating the root cause and delaying commercial supplies until the issue is resolved. The once-daily oral drug is available in 3 mg, 7 mg, and 14 mg strengths, priced at Rs 99, Rs 135, and Rs 225 per tablet, respectively.